Mylan Boss Tried To Calm Epipen Furor

Medical Celia Hoffman
http://i2.wp.com/stocknewsusa.com/wp-content/uploads/2016/08/1472090422447.jpg?fit=620%2C347

Heather Bresch is the 47-year old chief executive of the generic pharmaceutical giant Mylan. The company has been the center of a storm of criticism and media analysis after the company raised the costs of their EpiPen by 400 percent to $600 for two EpiPens. The EpiPen delivers a measured dose of epinephrine that is considered to be life saving for people who have allergic reactions to foods or insect bites.

Bresch took to Twitter and the media on August 26, 2016, to defend her company and to defend her $19 million dollar a year salary. Mylan has a monopoly on the manufacture and distribution of the EpiPen since the FDA found potential health risks with their competitor’s version.

Bresch announced that the company would immediately increase the level of financial assistance to people who could not afford the out of pocket costs for the EpiPen. Mylan has no control over any insurance company’s decision about covering the cost of the EpiPen.

Bresch stated that she had no problem with a company that could do good and do well meaning that Mylan did good for people who had serious ailments and did financially well for investors and for Bresch. Bresch is responsible for the move of the organization to Holland where the tax rate is lower than the U. S. The company does have a documented record of improving drug quality standards throughout the pharmaceutical industry.

Much of the criticism of Mylan and Bresch stems from the concept that generic drugs and generic drug manufacturers would provide lower prices than other pharmaceutical companies. The acquisition of companies and formulations by Mylan has made the company as large as any other pharmaceutical giant and the company is operating like their competitors according to Bresch.